Viking Therapeutics Inc (NAS:VKTX)
$ 62.76 1.98 (3.25%) Market Cap: 6.95 Bil Enterprise Value: 5.80 Bil PE Ratio: 0 PB Ratio: 7.32 GF Score: 38/100
Back to the Transcripts List

Q2 2024 Viking Therapeutics Inc Earnings Call Transcript

Jul 24, 2024 / 08:30 PM GMT
Release Date Price: $50.41 (-2.19%)

Key Points

Positve
  • Viking Therapeutics Inc (VKTX) announced positive results from the Phase II VENTURE trial evaluating VK2735 for obesity treatment, showing significant weight reductions.
  • The company reported encouraging results from a Phase I trial of an oral formulation of VK2735, demonstrating weight loss and excellent tolerability.
  • Positive 52-week histology results from the Phase IIb VOYAGE trial for VK2809 in NASH and fibrosis treatment were achieved, meeting secondary and exploratory endpoints.
  • Viking Therapeutics Inc (VKTX) presented promising preclinical data on dual agonists of the amylin and calcitonin receptors, showing potential for obesity treatment.
  • The company ended the second quarter with a strong balance sheet, holding over $900 million in cash, providing resources to advance pipeline programs.
Negative
  • Research and development expenses increased significantly to $23.8 million for Q2 2024, up from $13.9 million in Q2 2023, primarily due to higher manufacturing and clinical study costs.
  • General and administrative expenses rose to $10.3 million for Q2 2024, compared to $9.8 million in Q2 2023, driven by increased stock-based compensation and third-party consultant services.
  • Viking Therapeutics Inc (VKTX) reported a net loss of $22.3 million for Q2 2024, higher than the $19.2 million net loss in Q2 2023.
  • The company faces uncertainties regarding the scalability and commercial demand for its oral peptide formulations, which could impact future supply and production costs.
  • Despite positive trial results, the company still needs to conduct further studies and regulatory meetings, which could delay the commercialization of its drug candidates.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

VKTX.OQ - Viking Therapeutics Inc
Q2 2024 Viking Therapeutics Inc Earnings Call
Jul 24, 2024 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Operator [1]
--------------------------------------------------------------------------------
Welcome to the Viking Therapeutics Second Quarter 2024 financial results conference call. At this time, all participants are in a listen only mode. Following management's prepared remarks, we will hold a Q&A session to ask a question. At that time, please press star keys followed by one on your touchtone phone. Anyone has difficulty hearing the conference, please press star zero for operator assistance. As a reminder, this conference call is being recorded today, July 24th, 2024.

I would now like to turn the conference over to Viking's Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.

--------------------------------------------------------------------------------
Unidentified_2 [2]
Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.